Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Irritable Bowel Syndrome (IBS) Treatment Market Forecast Highlighting Growth From $7.97 Billion To $10.64 Billion
The market for irritable bowel syndrome (IBS) treatments has experienced robust expansion recently, with projections indicating a continued upward trend. This market is expected to increase from $7.41 billion in 2025 to $7.97 billion in 2026, fueled by a compound annual growth rate (CAGR) of 7.6%. Factors contributing to this historical growth include a surge in gastrointestinal disorder occurrences, heightened diagnosis rates for IBS, escalating public consciousness regarding digestive wellness, the broader accessibility of prescription medications for IBS, and the expansion of both hospital-based and retail pharmacy infrastructures.
The market for irritable bowel syndrome (IBS) treatments is poised for substantial expansion in the coming years. Projections indicate a market valuation of $10.65 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.5%. This anticipated growth throughout the forecast period is underpinned by several key factors, including progress in personalized medicine, the escalating use of digital health solutions, an increased reliance on online pharmacies, a heightened emphasis on research into the human microbiome, and a greater allocation of healthcare spending towards managing chronic ailments. Significant trends anticipated during this timeframe encompass the rise of precision medicine and therapies targeting the microbiome, the integration of digital therapeutics and mobile health applications, the utilization of artificial intelligence for optimizing IBS diagnosis and treatment, the implementation of remote patient monitoring alongside innovative gut health monitoring devices, and a shift towards developing drugs that are both sustainable and centered around the patient’s needs.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11978&type=smp
Irritable Bowel Syndrome (IBS) Treatment Market Growth Drivers And Industry Catalysts
The escalating incidence of Irritable Bowel Syndrome is anticipated to be a significant driver for the expansion of the IBS treatment market. IBS, a long-term condition affecting the large intestine, manifests through symptoms like abdominal discomfort, bloating, and changes in bowel habits, thereby diminishing an individual’s overall well-being. Factors such as contemporary lifestyle choices, encompassing inadequate dietary habits, elevated stress levels, and exposure to environmental irritants, are contributing to a greater number of people developing this condition. To address patient requirements, the IBS treatment market offers a dual approach consisting of pharmaceutical treatments, including antispasmodics and medications specifically targeting the gut, alongside non-drug interventions such as cognitive behavioral therapy, hypnotherapy, and dietary modifications. This growing need is underscored by data, for example, from the IBD Registry in the UK, which reported over 5,300 individuals with Inflammatory Bowel Disease by 2023, representing a substantial increase from the previous year. Consequently, the increasing prevalence of IBS is directly fueling the growth of its corresponding treatment market.
Irritable Bowel Syndrome (IBS) Treatment Market Segment Analysis Highlighting Growth Areas
The irritable bowel syndrome (ibs) treatment market covered in this report is segmented –
1) By Drug Type: Eluxadoline, Alosetron, Other Drugs
2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-Users: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Eluxadoline: IBS with Diarrhea (IBS-D) Treatment, Moderate IBS-D Treatment
2) By Alosetron: Severe IBS-D Treatment for Women, Refractory IBS-D Treatment
3) By Other Drugs: Prucalopride, Tenapanor, Plecanatide
#Irritable Bowel Syndrome (IBS) Treatment Market Trends Influencing Long-Term Demand
Key players within the irritable bowel syndrome (IBS) treatment sector are prioritizing the integration of digital health solutions, specifically mobile applications grounded in gut-directed hypnotherapy, to bolster patient interaction, ease of access to care, and effective symptom control. These digital therapeutic tools function as prescribed mobile platforms delivering structured hypnotherapy sessions via smartphones with the aim of influencing the gut-brain connection, thereby facilitating features like guided behavioral interventions, immediate symptom logging, and automated oversight of patient progress. To illustrate, in May 2023, the Canadian digital health firm Launchit DTx introduced Regulora. This digital therapeutic, utilizing gut-directed hypnotherapy, was developed to assist adults in managing the abdominal discomfort linked to IBS, incorporating hypnotherapy content supported by scientific research, prescribing processes facilitated for healthcare providers, and a mobile application that monitors patient outcomes throughout their treatment journey. By providing a non-medicinal and digitally dispensed therapeutic alternative, Regulora enhances both the availability of treatment options and the capacity for self-management, ultimately contributing to more comprehensive symptom alleviation for individuals with IBS.
Irritable Bowel Syndrome (IBS) Treatment Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the irritable bowel syndrome (ibs) treatment market are Ironwood Pharmaceuticals Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Johnson & Johnson Services Inc., AstraZeneca plc, Novartis AG, Abbott Laboratories, Eli Lilly and Company, Astellas Pharma Inc., Bausch Health Companies Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Renexxion Ireland Ltd., 4D Pharma plc, Biora Therapeutics Inc., Salix Pharmaceuticals Ltd., Allergan plc, Synergy Pharmaceuticals Inc.
Access The Complete Irritable Bowel Syndrome (IBS) Treatment Market Report:
Irritable Bowel Syndrome (IBS) Treatment Market Geographic Distribution And Regional Opportunities
North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (ibs) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
